Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
189
resultados
Última actualización
15/03/2026 [06:55:00]
Resultados 125 a 150 de 189
Resumen de: CN121606078A
本发明属于食品科学与功能材料领域，涉及一种负载蓝莓花色苷的果胶纳米颗粒的制备方法及其应用，将蓝莓进行匀浆，超声提取，收集滤液，浓缩，冻干得到蓝莓花色苷粉末；将过滤得到的蓝莓残渣进行干燥、粉碎过筛，进行水解提取，滤液进行离心，加入乙醇，过滤收集蓝莓湿果胶，漂洗，干燥、粉碎形成蓝莓果胶；将蓝莓花色苷配成溶液，将蓝莓果胶配成溶液，将两种溶液混合，超声，离心、冻干、固化成型，得到负载蓝莓花色苷的果胶纳米颗粒。通过果胶包埋形成纳米颗粒，能显著提升花色苷在口腔、胃、肠等消化阶段的保留率。对DPPH、ABTS、羟基自由基的清除能力均有提升，有较强的抗氧化活性。有助于推动蓝莓花色苷在营养强化、医药等领域的应用。
Resumen de: CN121606551A
本申请涉及一种纳米制剂及其制备方法和应用，具体涉及生物医用材料技术领域。所述纳米制剂具有核壳结构，包括核心和外壳，所述核心包括光敏剂和糖代谢抑制剂，所述外壳包括两亲性聚合物，其中，所述光敏剂为近红外二区荧光染料TTQ‑BT‑TPA，所述糖代谢抑制剂包括氯尼达明，所述两亲性聚合物包括1,2‑二硬脂酰基‑sn‑甘油‑3‑磷酸乙醇胺‑聚乙二醇2000。本申请提供的纳米制剂，以解决相关技术中传统光动力疗法因依赖氧气而在肿瘤缺氧区疗效受限、肿瘤细胞因代谢重编程维持高水平抗氧化防御系统导致对铁死亡不敏感、以及现有协同治疗体系因缺乏对肿瘤代谢的精准干预且光敏剂聚集态下荧光与活性氧产率降低而导致协同效果不佳的问题。
Resumen de: CN121606601A
本发明涉及生物医药技术领域，具体涉及一种芳胺类衍生物修饰的金纳米颗粒及其制备方法与应用。本发明提供的芳胺类衍生物修饰的金纳米颗粒能够提高非小细胞肺癌细胞内质网应激水平，还能够提高非小细胞肺癌细胞对化疗药物的敏感度，与化疗药物协同提高非小细胞肺癌细胞的死亡率。
Resumen de: CN121606598A
本发明属于生物医药技术领域，提供了一种siRNA及其应用。上述siRNA能够引起THADA基因沉默，可用于制备高脂血症、脂肪性肝病、动脉粥样硬化性心血管病等脂代谢疾病的预防或治疗药物。
Resumen de: WO2026006579A1
Compounds are provided having the following structure: (I), or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, wherein Y, Q, R, Ri, R2, m, n and o are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided. Formula (I).
Resumen de: US20260061028A1
Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).
Resumen de: US20260062716A1
The present disclosure relates generally to lipid nanoparticle compositions comprising a nucleic acid, an ionizable polymer, a cationic lipid, a phospholipid, a sterol, and a PEG-lipid. Further, the present disclosure relates generally to methods of treating or preventing a disease, comprising administering to a subject in need thereof a lipid nanoparticle composition described herein.
Resumen de: WO2026046237A1
Provided is a lung-targeting lipid compound, specifically relating to a compound as shown in formula (I), or an isotopic variant, tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt thereof. Also provided are a nanoparticle pharmaceutical composition comprising the compound, and a use of the compound and the composition thereof in lung targeted delivery of nucleic acids.
Resumen de: WO2026045510A1
Provided are a metal-organic framework nanomaterial, a preparation method therefor, and a use thereof, belonging to the technical field of bionanomaterials, and resolving the technical problem of inhibiting atherosclerosis using biomimetic metal-organic framework nanoenzymes. The solution is: the components of the of the metal-organic framework nanomaterial and the ratio thereof are: metal ions Ce4+ and a ligand fumaric acid in a molar ratio of 1:5. The preparation method therefor is: measuring an FA regulator and water to prepare a mixed solution, then adding fumaric acid and cerium ammonium nitrate dropwise into the mixed solution, stirring at room temperature, centrifuging, repeatedly washing alternately with water and ethanol, and finally drying overnight in a vacuum oven. A simple, efficient and convenient method for synthesizing the metal-organic framework nanomaterial is provided. The synthesized metal-organic framework nanomaterial has excellent CEH-like enzyme activity and intrinsic antioxidant activity, and can be used to increase lipid efflux and reduce lipid uptake, and decrease ox-LDL-induced foam cell formation, thereby alleviating atherosclerosis.
Resumen de: WO2026047519A1
Described herein are pharmaceutical compositions and methods of their use for the treatment of cancer. The pharmaceutical compositions comprise a first anticancer drug formulated as nanoparticles or microparticles, the nanoparticles or microparticles uniformly dispersed in the injectable hydrogel polymer matrix formulation. This matrix comprises an anionic polymer and an inverse thermal gelling polymer, which transitions from a liquid to a gel state at specific temperatures and demonstrates shear-thinning properties to facilitate injection and gel reformation. The pharmaceutical compositions are administered intratumorally into solid tumors to treat cancer in a subject requiring such treatment. The method may additionally include systemic administration of a therapeutically effective amount of a second anticancer drug.
Resumen de: WO2026048880A1
The present invention provides a nanoparticle with which it is possible, safely, efficiently, and stably over a long period of time, to introduce siRNA used for RNA interference into an intervertebral disk cell. This nanoparticle is used for prevention or treatment of intervertebral disk degeneration, and has a biodegradable hydrogel and a ribonucleic acid molecule that is retained by a particle of the biodegradable hydrogel and that selectively inhibits an activity of a mammalian target of rapamycin (mTOR) complex.
Resumen de: WO2026049467A1
The present invention relates to a composition for alleviating or treating hair loss in which a hair loss drug is loaded in lipid nanoparticles. The lipid nanoparticles contain 0.30 mol% or more of a hydrophobic drug such as finasteride or dutasteride relative to the lipid nanoparticles and are loaded with the hydrophobic drug at an encapsulation rate of 90.0% or more, and thus have the advantage of being able to maintain water dispersibility for a long period of time while increasing transdermal delivery. Therefore, the present invention can more effectively alleviate symptoms of male pattern hair loss on the scalp where localized hair loss or thinning of hair occurs.
Resumen de: WO2026049650A1
The invention relates to the fields of colloidal chemistry and medicinal chemistry. A surfactant containing branched hydrophobic chains with amino acid residues at the branching point is characterized by general formula (I), where R1-A-R2 represents an amino acid residue; k can be equal to 1, 2 or 3; l can be equal to 3, 4, 5, 6 or 7; the amino acid residue has an L configuration; R1 and R2 are the same or different residues from the list shown; m is an integer from 4 to 13. New compounds are obtained which provide for better binding of molecules inside lipid nanoparticles (LNPs), as well as more uniform packing of molecules inside LNPs, without the formation of ordered phases such as a lamellar phase.
Resumen de: WO2026050140A1
A modified nanoparticle nanocarrier system for delivering one or more active ingredients into a skin that can slowly release the active ingredients is provided. The modified nanoparticle nanocarrier system comprises a dendrimer, a linker and a peptide, wherein the dendrimer is first coated with the linker to form a dendrimer-linker conjugate, and the dendrimer-linker conjugate is then coupled to a peptide to form a dendrimer-linker-peptide conjugate. Subsequently, the dendrimer-linker-peptide conjugate is loaded with one or more active ingredients and mixed with a topical base to form a homogenized product to be applied onto the skin.
Resumen de: WO2026050148A1
Non-viral gene therapy treatments have a number of advantages over viral vectors including typical non-antigenicity, low manufacturing cost, simplicity, and efficiency of delivering genetic cargo into the cytoplasm. The potency of non-viral gene therapy systems can be enhanced by providing them with means to more efficiently transport the delivered DNA from the cytoplasm to the nucleus. Provided herein, at least in part, are means of enhancing potency of non-viral gene therapies by including novel nuclear translocation enhancing sequences and compositions that can result in optimized nuclear translocation as well as related compositions and methods.
Resumen de: WO2026050750A1
The present invention is related to compositions and methods for modifying the hepatitis B virus (HB V) genome using CRISPR gene editing technology to treat a subject suffering from HBV. The present invention is also related to compositions of modified HB V genomes.
Resumen de: WO2026050738A1
The present disclosure provides polymeric nanoparticles including block copolymers which possess reactive oxygen species (ROS) quenching units to reduce oxidative stress to prevent neurodegeneration and which can also be used to encapsulate an active pharmaceutical ingredient, a diagnostic marker, or a combination thereof in a pharmaceutical composition. The polymeric nanoparticles of the present disclosure are designed to release ROS quenchers, the active pharmaceutical ingredient, the diagnostic marker, or the combination thereof upon exposure to a pH below about 6.5, exposure to a reactive oxygen species, or a combination thereof. Methods of diagnosing or treating radiotherapy-induced brain injuries in a patient are also described.
Resumen de: WO2026045748A1
The present invention relates to the use of tRNA in promoting the protein-coding ability of mRNA. The expression level of a target protein is improved by means of overexpressing tRNA, and a codon corresponding to the tRNA can promote or improve the stability of the mRNA. Further provided is a new tRNA+mRNA immunopotentiating vaccine. By means of introducing one or more tRNA molecules, the antigen protein encoding ability of an mRNA vaccine is enhanced, thereby eliciting stronger humoral and cellular immune responses in vivo. Further provided is a recombinant cell for producing an antibody. The recombinant cell overexpresses tRNA capable of increasing the expression level of the antibody, and the tRNA comprises a tRNA isodecoder family. Further provided is a recombinant cell for producing or packaging recombinant AAV, wherein the recombinant cell overexpresses tRNA capable of improving the AAV packaging efficiency.
Resumen de: WO2026047271A1
The present invention relates to a nanoparticle system comprising a metal selected from silver and gold, coated with polyethylene glycol (PEG) and functionalised with a polyphenol organic acid selected from caffeic acid, gallic acid and ferulic acid. The present invention also relates to a method for manufacturing said nanoparticle system and to the therapeutic and cosmetic use of said nanoparticle system.
Resumen de: WO2026047578A1
The present invention relates to a method for synthesising a photosensitive polyethylene glycol (PEG) and methyl ether-poly(d,l-lactide) (PDLLA) polymer by tosylating its organic group. The photosensitive PEG-PDLLA polymer is functionalised by opening the Lactide monomer ring by polymerising and covalently bonding with the alcohol terminal group of PEG via an esterification with the tosylated organic group. The nanopolymer obtained using the disclosed method is suitable for controlled release processes of hydrophobic and hydrophilic active ingredients with specific delivery based on photodynamic therapy. The PEG-PDLLA-based nanopolymer obtained is able to encapsulate hydrophobic and hydrophilic active ingredients, configuring a nanocarrier with amphiphilic filler with high potential for photodynamic therapy. The method in turn involves nanoprecipitation by removing the organic solvent with optimal photo response properties to UV light.
Resumen de: WO2026049199A1
The present invention relates to a pH-sensitive nanoparticle-based drug delivery system which can be used for cancer treatment. The drug delivery system comprises: nanoparticles comprising a drug and having a linker on the surface thereof; and a fusion protein comprising a polypeptide which binds to the linker and an antibody which specifically binds to a tumor, wherein the drug is characterized by being eluted from the nanoparticles in a tumor microenvironment, thereby making it possible to minimize side effects such as toxicity to normal tissues and maximize therapeutic effects on the tumor.
Resumen de: WO2026050318A1
Provided herein are compositions and methods for modifying the human gene, APOC3. Such compositions and methods may result in the reduction of the protein, apolipoprotein C3 (apoC-III) when administered to a human subject. Compositions and methods provided herein may comprise a CRISPR-associated (Cas) protein or uses thereof. Compositions and methods of the present disclosure may be useful for treatment of APOC3 associated conditions, including persistent chylomicronemia, familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (SHTG).
Resumen de: WO2026050432A1
The present disclosure provides modified flavivirus polypeptides useful as antigens and polynucleotides encoding the same, and related compositions, methods of making, and methods of using. Also provided herein are enveloped virus-like particles and cells comprising all or a portion of said modified flavivirus polypeptides. In particular, these modified flavivirus polypeptides are useful for eliciting an immune response against flavivirus infection.
Resumen de: AU2026200990A1
The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Anionic phospholipids, including phosphatidyl serine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. The further incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-di oxolane or heterocyclic ketal ionizable lipids in the formulation demonstrated high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Finally, the use of an ammonium salt of phosphatidylserine allows for the efficient production of PS-targeted LNPs. 20 eb e b
Nº publicación: AU2026200991A1 05/03/2026
Solicitante:
AKAGERA MEDICINES INC
AKAGERA MEDICINES, INC
Resumen de: AU2026200991A1
Aspects of the present disclosure provide for improved mycobacterium tuberculosis vaccine compositions of ionizable lipid nanoparticles for the delivery of immunogenic nucleic acids to cells. Anionic phospholipids, including phosphatidyl serine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in dendritic cells. In some embodiments, the incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation provided high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Other aspects of the present disclosure provide mRNA that encodes for concatenated peptides encoding for multiple MHC-II tuberculosis epitopes, and optionally includes a second mRNA encoding for concatenated MHC-I tuberculosis epitopes. eb e b
BOPI
Sede Electrónica
